Pacer Advisors Inc. Decreases Stake in argenx SE (NASDAQ:ARGX)

Pacer Advisors Inc. lessened its stake in shares of argenx SE (NASDAQ:ARGX) by 5.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 789 shares of the company’s stock after selling 43 shares during the quarter. Pacer Advisors Inc.’s holdings in argenx were worth $485,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after buying an additional 21 shares during the period. Raymond James Trust N.A. increased its position in argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock valued at $268,000 after purchasing an additional 28 shares during the period. Hantz Financial Services Inc. raised its holdings in argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock worth $286,000 after purchasing an additional 43 shares in the last quarter. Aaron Wealth Advisors LLC raised its holdings in argenx by 10.1% in the 4th quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock worth $301,000 after purchasing an additional 45 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares during the period. Institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ARGX. Raymond James reissued a “strong-buy” rating and issued a $605.00 price target on shares of argenx in a research note on Thursday, October 10th. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and issued a $675.00 price target (up from $646.00) on shares of argenx in a research note on Thursday, November 21st. Deutsche Bank Aktiengesellschaft lowered argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Finally, William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, argenx has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Stock Performance

NASDAQ ARGX opened at $651.30 on Wednesday. The stock has a 50-day moving average of $634.50 and a 200 day moving average of $573.66. The company has a market capitalization of $39.57 billion, a price-to-earnings ratio of -740.11 and a beta of 0.58. argenx SE has a one year low of $349.86 and a one year high of $678.21.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.